Bill Overview
Title: American Made Pharmaceuticals Act of 2022
Description: This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
Sponsors: Rep. Craig, Angie [D-MN-2]
Target Audience
Population: People globally dependent on drugs with vulnerable supply chains during public health emergencies
Estimated Size: 120000000
- The bill affects individuals who are enrolled in Medicare, Medicaid, and Children’s Health Insurance Program (CHIP), which together cover a substantial portion of the US population, including elderly citizens, low-income individuals, and children.
- It influences individuals who are reliant on critical drugs during public health emergencies, particularly those drugs identified as having vulnerable supply chains.
- This could impact healthcare consumers nationwide, but more directly in the states selected for the demonstration program.
- Domestically manufactured drug preference may affect consumers by changing the cost or availability of certain drugs.
Reasoning
- The simulated interviews should cover a range of individuals across different age groups, occupations, and locations to capture the diverse impacts of the policy.
- Those most directly impacted would likely be those who rely heavily on programs like Medicare and Medicaid and take medications that fall under the eligible categories of critical drugs.
- Some individuals in areas where the demonstration program is conducted might experience a direct impact, especially if they use the specific drugs mentioned.
- Others, whose drugs are not affected or who are not in the demonstration states, may see little to no change in their wellbeing scores.
Simulated Interviews
Retired (Ohio)
Age: 70 | Gender: female
Wellbeing Before Policy: 6
Duration of Impact: 20.0 years
Commonness: 15/20
Statement of Opinion:
- I worry about where my insulin comes from, especially if there are issues with the supply chain.
- Having domestically produced medications could offer peace of mind and potentially lower out-of-pocket costs.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 6 |
| Year 2 | 7 | 6 |
| Year 3 | 7 | 6 |
| Year 5 | 8 | 6 |
| Year 10 | 8 | 5 |
| Year 20 | 9 | 5 |
Self-employed contractor (California)
Age: 35 | Gender: male
Wellbeing Before Policy: 5
Duration of Impact: 7.0 years
Commonness: 13/20
Statement of Opinion:
- Any reduction in medication costs is beneficial, especially when it comes to my kids' health.
- I haven't heard much about the program yet, but it sounds like it could lessen our financial burden.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 5 |
| Year 2 | 6 | 5 |
| Year 3 | 7 | 5 |
| Year 5 | 7 | 5 |
| Year 10 | 7 | 5 |
| Year 20 | 6 | 5 |
Teacher (Texas)
Age: 29 | Gender: female
Wellbeing Before Policy: 6
Duration of Impact: 5.0 years
Commonness: 10/20
Statement of Opinion:
- It sounds like it might help during health emergencies, but I'm not sure it will impact my allergy medication costs.
- If it does, that would be great, but I'm skeptical.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 6 | 6 |
| Year 5 | 6 | 6 |
| Year 10 | 6 | 6 |
| Year 20 | 6 | 6 |
Engineer (Florida)
Age: 52 | Gender: male
Wellbeing Before Policy: 7
Duration of Impact: 0.0 years
Commonness: 8/20
Statement of Opinion:
- I've had a stable experience with my medication, so I'm not sure how much this policy will affect me.
- Still, supporting local manufacturing of drugs seems like a good step in case of crisis.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 7 | 7 |
| Year 3 | 7 | 7 |
| Year 5 | 7 | 7 |
| Year 10 | 7 | 7 |
| Year 20 | 7 | 7 |
Unemployed (New York)
Age: 45 | Gender: male
Wellbeing Before Policy: 3
Duration of Impact: 15.0 years
Commonness: 5/20
Statement of Opinion:
- It's hard to find the medication I need, and costs can be extreme.
- Anything that reduces costs or increases availability is desperately needed.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 4 | 3 |
| Year 2 | 5 | 3 |
| Year 3 | 5 | 3 |
| Year 5 | 6 | 3 |
| Year 10 | 6 | 3 |
| Year 20 | 6 | 3 |
Nurse (Indiana)
Age: 60 | Gender: female
Wellbeing Before Policy: 7
Duration of Impact: 10.0 years
Commonness: 9/20
Statement of Opinion:
- During the pandemic, we experienced delays in medication.
- This policy seems like it could prevent that sort of stress from happening again.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 8 | 7 |
| Year 3 | 8 | 7 |
| Year 5 | 8 | 7 |
| Year 10 | 8 | 7 |
| Year 20 | 8 | 7 |
Software Developer (Oregon)
Age: 40 | Gender: other
Wellbeing Before Policy: 6
Duration of Impact: 7.0 years
Commonness: 12/20
Statement of Opinion:
- While I'm not directly affected, anything that helps my partner with medication costs is beneficial.
- This sounds positive if it genuinely decreases costs or improves access.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 6 | 6 |
| Year 5 | 7 | 6 |
| Year 10 | 7 | 6 |
| Year 20 | 7 | 6 |
Retail Worker (Georgia)
Age: 38 | Gender: female
Wellbeing Before Policy: 5
Duration of Impact: 0.0 years
Commonness: 16/20
Statement of Opinion:
- If this affects prescribed cold medications, that would be helpful but if not, I don't think it will affect us.
- Many families like ours struggle with medication costs consistently.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 5 | 5 |
| Year 2 | 5 | 5 |
| Year 3 | 5 | 5 |
| Year 5 | 5 | 5 |
| Year 10 | 5 | 5 |
| Year 20 | 5 | 5 |
Retired (Illinois)
Age: 72 | Gender: male
Wellbeing Before Policy: 6
Duration of Impact: 20.0 years
Commonness: 11/20
Statement of Opinion:
- The supply chain issues worry me regarding my heart medication.
- I'd support anything that makes sure it's consistently available and affordable.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 6 | 6 |
| Year 5 | 7 | 6 |
| Year 10 | 7 | 6 |
| Year 20 | 7 | 6 |
Farmer (Nebraska)
Age: 50 | Gender: female
Wellbeing Before Policy: 5
Duration of Impact: 10.0 years
Commonness: 7/20
Statement of Opinion:
- Program sounds promising if it deals with the availability and cost of allergy meds.
- Past shortages have been stressful and debilitating.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 5 |
| Year 2 | 6 | 5 |
| Year 3 | 6 | 5 |
| Year 5 | 7 | 5 |
| Year 10 | 7 | 5 |
| Year 20 | 6 | 5 |
Cost Estimates
Year 1: $1500000000 (Low: $1000000000, High: $2000000000)
Year 2: $1300000000 (Low: $900000000, High: $1800000000)
Year 3: $1300000000 (Low: $900000000, High: $1800000000)
Year 5: $1500000000 (Low: $1000000000, High: $2000000000)
Year 10: $0 (Low: $0, High: $0)
Year 100: $0 (Low: $0, High: $0)
Key Considerations
- Scale and scope of the demonstration program and its replication in other states.
- Challenges in scaling domestic production capacity for pharmaceuticals.
- Potential resistance from global pharmaceutical providers due to changed sourcing requirements.
- Impact on drug prices and consumer cost-sharing both short-term and long-term.